Send us Fan Mail

🧪 Trials:

RESHAPE-HF2: ↓ HF hospitalizations with transcatheter edge-to-edge repair vs medical therapy.

MATTR: Transcatheter approach non-inferior to surgical repair.

🧩 Clinical Takeaway:

Game-changing for patients too high risk for surgery.

Less peri-op risk, faster recovery — mitral repair is heading the way of TAVR.

Send us Fan Mail

💊 Study:

SURMOUNT-HF trial — patients with obesity and HFpEF.

Tirzepatide = ↓ HF hospitalizations and ↑ quality of life.

📈 Benefits:

Significant weight loss.

Better metabolic profiles.

GI side effects: ~6% (nausea, diarrhea).

🧩 Clinical Takeaway:

A major contender for cardio-metabolic syndrome with HFpEF.

More than just a diabetes or weight-loss drug.

Send us Fan Mail

🧪 Study:

Patients ≥55 with no relapses in 5 yrs and no new lesions in 3 yrs may stop disease-modifying therapy (DMT).

No significant difference in disability progression.

🧩 Clinical Takeaway:

De-escalation strategy in stable MS may reduce cost and side effects.

Still requires close neurology follow-up.

Send us Fan Mail

🧠 Clinical Tool:

Spot urine sodium 2 hours after IV loop diuretic.

If <50–70 mmol/L → inadequate response.

Consider doubling dose or switching loop agents.

💡 Tips:

Also assess urine output in first 6 hours (<100–150 mL/hr = poor response).

Less helpful after 24 hrs or in chronic diuretic users.

🧩 Clinical Takeaway:

Fast, practical guide to assess diuretic effectiveness in acute decompensated HF.

Send us Fan Mail

🧪 Key Findings:

Cohort study: SGLT2 inhibitors led to significantly lower rates of nephrolithiasis compared to GLP-1 RAs.

Mechanism: increased urinary flow and uric acid excretion.

🔢 Stats:

NNT = 20 for prevention.

NNT = 5 for recurrent stone formers.

🧩 Clinical Takeaway:

Another bonus benefit of SGLT2 inhibitors.

May sway decision in diabetics prone to stones.

HCTZ no longer holds the same weight in stone prevention.

Send us Fan Mail

🧪 Key Insights:

Observational data links semaglutide (GLP-1 RA) to increased risk of non-arteritic anterior ischemic optic neuropathy (NAION).

Incidence: ~9–15 cases per 100,000 patient-years.

Possible mechanism: GLP-1 receptors in optic nerve ganglion cells.

No proven causality yet — retrospective study only.

🧩 Clinical Takeaway:

Risk remains very low.

Discuss with patients who have eye disease or prior NAION before initiating therapy.

Send us Fan Mail

🧪 VOYAGER-PAD Trial:

Patients with PAD post lower extremity revascularization.

Rivaroxaban 2.5 mg BID + aspirin vs aspirin alone.

📈 Results:

↓ Major Adverse CV Events (MACE).

↓ Major Adverse Limb Events (MALE).

Modest ↑ in bleeding — no ↑ in fatal bleeds.

🧩 Clinical Takeaway:

Now guideline-endorsed for symptomatic PAD post-intervention.

Risk-benefit conversation needed in high-bleed-risk patients.

Send us Fan Mail

🧠 Problem:

RLS causes chronic sleep disruption, often worsens in hospital or peri-op settings.

💊 Management:

First-line: Gabapentin or Pregabalin (per American Academy of Sleep Medicine).

Avoid long-term dopamine agonists — cause augmentation and impulse control disorders.

🩸 Bonus Tip:

Check ferritin — keep it >75 ng/mL.

Oral or IV iron can help symptom control.

🧩 Clinical Takeaway:

Treat aggressively; it’s more than “just annoying.”

Avoid benzos and older agents unless no better option.

Send us Fan Mail

🧪 Study:

Retrospective look at patients with intracranial hemorrhage (ICH) on warfarin for mechanical valves.

Followed for stroke, rebleed, mortality.

📈 Findings:

Only 2 strokes in first 7 days after stopping warfarin.

Most resumed warfarin around day 7 with low rebleed risk.

⚠️ Exclusions:

Massive bleeds, unstable patients, large hematomas may require longer delay.

🧩 Clinical Takeaway:

Restarting warfarin at 7 days appears safe in stable patients.

Still a team-based call — include cardiology, neurology, neurosurgery.

Send us Fan Mail

📊 What It Is:

A modern CV risk estimator developed from 2.3 million-person dataset.

Replaces outdated ASCVD calculator (based on 25k).

🧠 Features:

Adds BMI, GFR, A1C, and zip code.

Omits race — more equitable.

Outputs risk of heart disease, stroke, heart failure.

⚠️ Caveats:

Generally gives lower risk estimates vs ASCVD.

May reduce statin overuse, but some feel it's too conservative.

🧩 Clinical Takeaway:

Helpful in primary prevention — especially borderline cases.

Use side-by-side with ASCVD for now until guidelines update.